Process development for Trastuzumab production from Chinese Hamster Ovary (CHO) in laboratory scale

Authors

  • Nguyễn Quang Huy
  • Từ Tiểu My
  • Hứa Hoàng Quốc Huy
  • Nguyễn Trường An
  • Hà Tấn Phát
  • Nguyễn Thị Thùy Trang
  • Đinh Văn Long
  • Trịnh Thanh Hùng
  • Đỗ Minh Sĩ

Keywords:

CHO; culture medium; Trastuzumab

Abstract

Background: CHO cells have been commonly used in the production of recombinant protein. It is reported that around 70% of recombinant therapeutic proteins are produced in CHO cell systems and the market size exceeds 15£ billion per year. With the optimization of culture, conditions showed that CHO cell density could reach 18 million per cell per milliliter and a final product concentration of 01 - 05 g l-1. Therefore, the production process development on a laboratory scale plays an important role in identifying the optimal conditions suitable, which can be applied to produce Trastuzumab on a industrial scale. In this study, Trastuzumab-producing cell lines were investigated in step wise: culture medium, percentage of supplements, culture temperature and shaking speed. The result showed that the optimal conditions were as follows: cells were shaken at 100rpm in ActiPro medium supplemented with Cell Boost 7a/7b (ratio 1:0.1%) daily from day 03, the initial growth temperature was 37oC then shifted to 32oC on day 05.

After 14 days, cell density reaches over 25 million per cell per milliliter, and Trastuzumab concentration collects around 04g/L.

Downloads

Download data is not yet available.

Author Biographies

  • Nguyễn Quang Huy

    Trường Đại học Khoa Học Tự Nhiên, ĐHQG-HCM
    Công ty CP Thuốc Thú Y TW Navetco, Việt Nam

  • Từ Tiểu My

    Công ty CP CNSH Dược Nanogen, Việt Nam

  • Hứa Hoàng Quốc Huy

    Công ty CP CNSH Dược Nanogen, Việt Nam

  • Nguyễn Trường An

    Công ty CP CNSH Dược Nanogen, Việt Nam

  • Hà Tấn Phát

    Công ty CP CNSH Dược Nanogen, Việt Nam

  • Nguyễn Thị Thùy Trang

    Công ty CP CNSH Dược Nanogen, Việt Nam

  • Đinh Văn Long

    Công ty CP CNSH Dược Nanogen, Việt Nam

  • Trịnh Thanh Hùng

    Bộ Khoa học và Công nghệ, Việt Nam

  • Đỗ Minh Sĩ

    Công ty CP CNSH Dược Nanogen, Việt Nam

Published

2022-11-28

Issue

Section

Bài viết